Veeda Clinical Research Limited
- Current price
- ₹428.00 Per share
- Market cap
- ₹2,990 Cr Total valuation
- P/E ratio
- N/A Price to earnings
- Sector
- Healthcare & Pharmaceuticals ISIN · INE01HQ01026 DRHP Filed Industry
About Veeda Clinical Research Limited
Veeda Clinical Research Limited operates in the Healthcare & Pharmaceuticals ISIN · INE01HQ01026 DRHP Filed sector. Its shares are not listed on stock exchanges like NSE or BSE and are traded through private transactions. On InvestShare, Veeda Clinical Research Limited shares are currently priced at ₹428.00 per share.
Shares in private companies can offer exposure before a potential IPO. They carry higher risk than listed stocks, so proper research and a long-term outlook are important.
Veeda Clinical Research Limited share FAQs
What is the Veeda Clinical Research Limited share price today?
The current Veeda Clinical Research Limited share price on InvestShare is ₹428.00 per share. Private-market share prices are indicative and may change.
How can I buy Veeda Clinical Research Limited shares?
Complete a simple KYC on InvestShare with your PAN, Aadhaar and demat account details, then place a buy request for Veeda Clinical Research Limited. After confirmation and settlement, the shares are transferred to your demat account through an off-market transaction.
Is a demat account required to buy Veeda Clinical Research Limited shares?
Yes, a demat account is required to hold Veeda Clinical Research Limited shares. The shares are credited to your demat account through an off-market transfer.
Key data & fundamentals
About Veeda Clinical Research Limited
About the Company Veeda Clinical Research Limited is one of the largest independent full-service clinical research organizations (CRO) in India. Established in 2004, the company has grown significantly, providing a broad range of clinical research solutions to the pharmaceutical industry globally. Business Model Veeda operates on a comprehensive business model offering end-to-end clinical research services, including pre-clinical, early phase, and late phase clinical trials. The company's approach is designed to deliver cost-effective and timely research solutions to pharmaceutical companies, thereby aiding in the development and launch of new drugs
- Indicative price
- ₹428.00
- Lot size
- 100
- 52 week high
- ₹460
- 52 week low
- ₹428
- Market cap
- ₹2,990 Cr
- No. of shares
- 6,98,58,503
- P/E ratio
- N/A
- P/B ratio
- 2.68
- ROE
- -1.26 %
- Book value
- ₹159.75
- Face value
- ₹2
- ISIN
- INE01HQ01026
- PAN
- AACCC3633Q
Indicative price history
Financial statements
- Revenue · FY26
- 715.5 ₹ Cr ▲Up17%
- EBITDA · FY26
- 209.6 ₹ Cr ▲Up68%
- Profit before tax · FY26
- 7.3 ₹ Cr ▲Up111%
- Net profit (PAT) · FY26
- -14 ₹ Cr ▲Up79%
- Operating margin · FY26
- 29.29% ▲Up43%
- EPS · FY26
- ₹-2 ▲Up80%
| Particulars | FY23 | FY24 | FY25 | FY26 | YoY |
|---|---|---|---|---|---|
| Revenue | 409 | 388 | 610 | 715.5 | ▲Up17% |
| EBITDA | 103 | 53 | 125 | 209.6 | ▲Up68% |
| OPM (%) | 25.18 | 13.66 | 20.49 | 29.29 | ▲Up43% |
| PBT | 59 | 3.3 | -66 | 7.3 | ▲Up111% |
| PAT | 42 | -0.3 | -67 | -14 | ▲Up79% |
| EPS (₹) | 8 | -0.04 | -10.19 | -2 | ▲Up80% |
| Particulars | FY23 | FY24 | FY25 | FY26 | YoY |
|---|---|---|---|---|---|
| Share capital | 10.5 | 13.599 | 13.155 | 13.97 | ▲Up6% |
| Reserves | 452 | 1,047 | 849 | 1,100 | ▲Up30% |
| Borrowings | 48 | 260 | 406 | 421.3 | ▲Up4% |
| Total assets | 735 | 2,040.2 | 1,863 | 2,038 | ▲Up9% |
| Total liabilities | 735 | 2,040.6 | 1,863 | 2,038 | ▲Up9% |
| Investments | 55 | 80 | 41 | 66 | ▲Up61% |
| Particulars | FY23 | FY24 | FY25 | FY26 | YoY |
|---|---|---|---|---|---|
| CFO | 106 | 58 | 33.5 | 239 | ▲Up613% |
| CF investing | -126 | -446 | -149.3 | -56 | ▲Up62% |
| CF financing | -1 | 399 | 91.4 | -83.5 | ▼Down191% |
| Net cash | -21 | 11 | -24.4 | 99.5 | ▲Up508% |
| Cash at end | 39 | 92 | 69.6 | 169.5 | ▲Up144% |